Last reviewed · How we verify
aP booster
At a glance
| Generic name | aP booster |
|---|---|
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
- Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa (PHASE4)
- 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination (PHASE4)
- Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
- A Study Exploring Whooping Cough Protection in Children and Adults (PHASE4)
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (PHASE3)
- Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years (PHASE1)
- Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aP booster CI brief — competitive landscape report
- aP booster updates RSS · CI watch RSS
- Novartis portfolio CI